Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2007-02-27
2007-02-27
Azpuru, Carlos A. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
Reexamination Certificate
active
09734460
ABSTRACT:
Methods and compositions for the prevention and treatment of all forms of atherosclerosis are described. Administration of compounds such as thalidomide, its analogs, hydrolysis products, metabolites, derivatives and precursors as well as additional compounds capable of inhibiting tumor necrosis factor α (TNF-α) are used in the invention.Also disclosed is the coating of prosthetic devices, such as stents, with the compounds of the invention for the prevention and/or treatment of restenosis.
REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 5059595 (1991-10-01), LeGrazie
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5593990 (1997-01-01), D'Amato
patent: 5605914 (1997-02-01), Muller
patent: 5629327 (1997-05-01), D'Amato
patent: 5635517 (1997-06-01), Muller et al.
patent: 5637113 (1997-06-01), Tartaglia et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5658940 (1997-08-01), Muller et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5698579 (1997-12-01), Muller
patent: 5703098 (1997-12-01), Muller et al.
patent: 5728844 (1998-03-01), Muller et al.
patent: 5728845 (1998-03-01), Muller et al.
patent: 5733566 (1998-03-01), Lewis
patent: 5736570 (1998-04-01), Muller et al.
patent: 5798368 (1998-08-01), Muller et al.
patent: 5801195 (1998-09-01), Muller et al.
patent: 5837313 (1998-11-01), Ding et al.
patent: 5849736 (1998-12-01), Wityak et al.
patent: 5874448 (1999-02-01), Muller et al.
patent: 5877200 (1999-03-01), Muller
patent: 0 688 771 (1995-12-01), None
patent: WO 96/11209 (1996-04-01), None
patent: WO 98/08840 (1998-03-01), None
patent: WO 99/06041 (1999-02-01), None
patent: WO 99/58096 (1999-11-01), None
patent: WO 00/10552 (2000-03-01), None
Stedman's Online Medical Dictionary, 27th Edition, 2000.
Grell et al (Mar., 1999), Tumor Necrosis Factor, Encyclopedia of Life Sciences.
Remington's Pharmaceutical Sciences, 18th Edition, pp. 665-668.
Worz et al., Treating dyslipidaemic patients with lipid-modifying and combination therapies, PHARMACOTHERAPY. May 23, 2003 (5):625-37.
Keating et al., Micronised Fenofibrate—An Updated Review of its Clinical Efficacy in the Management of Dyslipidaemia, DRUGS. 2002; 62 (13): 1909-1944.
Amols, et al., 1998, “Intracoronary radiation for prevention of restenosis: dose perturbations caused by stents”, Circulation 98(19):2024-9.
Bachelerie et al., 1991, “HIV enhancer activity perpetuated by NF-kappa B induction on infection of monocytes”, Nature 350(6320):709-12.
Blaschke et al., 1979, “Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers”, Arzneimittelforschung 29(10):1640-2.
Brem, et al. , 1991, “Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas”, J Neurosurg. 74(3):441-6.
Casini, et al. , 1964, Farmaco Ed. Sci. 19:563.
D'Amato et al., 1994, Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91(9):4082-5.
Dbaibo et al., 1993, “Tumor necrosis factor-alpha (TNF-alpha) signal transduction through ceramide. Dissociation of growth inhibitory effects of TNF-alpha from activation of nuclear factor-kappa B”, J Biol Chem. 268(24):17762-6.
Duh et al., 1989, “Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat”, Proc Natl Acad Sci U S A. 86(15):5974-8.
Eltchaninoff, et al., 1998, Balloon angioplasty for the treatment of coronary in-stent restenosis: immediate results and 6-month angiographic recurrent restenosis rate. J Am Coll Cardiol.32(4):980-4.
Libby et al., 1992, “A cascade model for restenosis. A special case of atherosclerosis progression”, Circulation. 86(6 Suppl):III47-52.
Moreno et al., 1996, “Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina”, Circulation 94(12):3098-102.
Muller, et al. “Thalidomide: From tragedy to new drug discovery”, 1997, Chemtech 27(1):21-25.
Shealy et al., 1965, “D- and L-thalidomide”, Chem Ind. 24:1030-1.
Suzuki and Packer. 1993, “Inhibition of NF-kappa B activation by vitamin E derivatives”, Biochem Biophys Res Commun. 193(1):277-83.
Takano, et al., 1998, “High levels of circulating Macrophage Colony Stimulationg Factor (M-CSF) Predict Restenosis After Primary Angioplasty in Patients With Acute Myocardial Infraction”, Circulation 98(17, supp):4437.
Tardif et al., 1991, “Probucol and multivitamins in the prevention of restenosis after coronary angioplasty”, N Engl J Med. 337(6):365-72.
Azpuru Carlos A.
Celgene Corporation
Jones Day
LandOfFree
Methods and compositions for the prevention and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the prevention and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the prevention and treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3826859